Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM)
tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
FRANKLIN, Mass., Nov. 4 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC
Bulletin Board: ECTE), a diabetes management company developing the
needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal
continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep
System for transdermal drug delivery announced today that it has initiated a
clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring
System (tCGM System) in patients with Type 1 and Type 2 diabetes. The purpose
of the study is to test the performance of its new one-piece, cost-effective
and easy-to-use biosensor. The Company expects to complete and announce the
results of the study in the fourth quarter of 2009.
"We are extremely pleased to take this next step forward in the development
work on our one piece biosensor, a critical component of Symphony, our
needle-free, continuous glucose monitoring technology," stated Patrick T.
Mooney, M.D., Chairman and CEO of Echo Therapeutics. "As we described
previously, this next generation biosensor introduces new materials and a more
effective geometrical construction designed to be one-piece and replaces the
prior prototype two-piece biosensor used in earlier clinical trials. We
believe that this biosensor will demonstrate improved performance and
reliability and we look forward to confirming this in this clinical trial in
Type 1 and Type 2 diabetics."
Echo's pilot clinical study will enroll patients with diabetes (either Type 1
or Type 2) and will compare data obtained from its Symphony tCGM System with
the "gold standard" YSI Glucose Analyzer. The study will collect
approximately 900 data pairs to be used in the analyses. Reference glucose
measurements will be made at 15 minute intervals for 24 hours with the study
data blinded to study subjects and study personnel.
About Echo Therapeutics
Echo Therapeutics is focused on medical devices and specialty pharmaceuticals.
Echo is developing the Symphony tCGM System as a non-invasive, wireless,
transdermal continuous glucose monitoring system for patients with diabetes
and for use in hospital critical care units. Echo is also developing its
needle-free Prelude SkinPrep System for transdermal drug delivery of a wide
range of novel topical reformulations of widely-used, FDA-approved products.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the efficacy of Echo's Symphony tCGM System, the failure of
future development and preliminary marketing efforts related to Echo's
Symphony tCGM System, Echo's ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to Echo's ability to
develop, market and sell diagnostic and transdermal drug delivery products
based on its skin permeation platform technologies, including the Symphony
tCGM System, the availability of substantial additional equity or debt capital
to support its research, development and product commercialization activities,
and the success of its research, development, regulatory approval, marketing
and distribution plans and strategies, including those plans and strategies
related to its Symphony tCGM System. These and other risks and uncertainties
are identified and described in more detail in Echo's filings with the
Securities and Exchange Commission, including, without limitation, its annual
report on Form 10-K for the year ended December 31, 2008, its quarterly
reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics,
Inc. undertakes no obligation to publicly update or revise any forward-looking
statements.
For More Information:
Patrick T. Mooney, M.D.
Chairman and Chief Executive Officer
(856) 429-8778
SOURCE Echo Therapeutics, Inc.
Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo
Therapeutics, Inc., +1-856-429-8778
